Astral Ltd’s record carries a clean audit trail and routine revenue recognition, but two things deserve attention: the Paints and Adhesives segment has seen its margins halve while carrying ₹294.6 crore of unimpaired goodwill, and the company has a pattern of using amalgamations to restate historical financials upward while routing operating costs through recurring exceptional charges.
Key findings
- Goodwill sits on a paints segment with a declining margin
Major- The Paints and Adhesives segment carries ₹294.6 crore of consolidated goodwill, yet its PBIT margin has fallen from 9.70% in FY2023 to 5.47% in FY2026. Only a ₹4.1 crore impairment was recognised in FY2026, on the goodwill of a US subsidiary. The standalone ₹370.7 crore investment in subsidiaries was a Key Audit Matter for impairment assessment in both FY2024 and FY2025. - Amalgamations restate historical numbers upward, and exceptional charges recur
Major- The 2022 amalgamation of Resinova Chemie and Astral Biochem restated FY2022 standalone revenue from 3,443.3 crore to 4,061.3 crore and net profit from 404.8 crore to 461.7 crore. In FY2026, the company booked ₹18.5 crore in exceptional items, continuing a pattern that included charges in FY2023 and FY2022. Management stated the paints business needed “a couple of year challenging time” to clean up the books of the acquired company. - Promoter family holds board control, and MD remuneration draws institutional dissent
Minor- Sandeep Engineer’s monthly salary is proposed at ₹96,54,515 for FY2027-28, plus a 1%-of-PBT incentive. His 2022 re-appointment drew 11.26% votes against overall, with public institutions voting 36.49% against. At the August 2024 AGM, the re-appointment of Jagruti Engineer as Whole-Time Director received 47.87% votes against from public institutions. - Shareholder approval obtained for ₹200 crore loan, guarantee, or security facility
Minor- In January 2024, the company sought shareholder approval for a ₹200 crore facility to give loans, guarantees, or provide security to subsidiaries, associates, joint ventures, or group entities, stating the Board was previously constrained by Section 185. The resolution passed with 75.78% votes in favour. CARO reporting for FY2026 confirms loan terms were not prejudicial and repayment of principal and interest was regular. - Revenue recognition is routine, with factoring kept on the balance sheet
Clean- The Group offers a standard credit period of up to 180 days, consistently disclosed from FY2021 through FY2026. Receivables sold to a factoring provider remain on the balance sheet because the Group underwrites the debts, with the outstanding amount growing from ₹23.3 crore in FY2021 to ₹61.5 crore in FY2026. Receivable days stand at 26.40 for FY2026.
What to watch
- Al-Aziz amalgamation. The amalgamation of Al-Aziz Plastics Private Limited into Astral Ltd, approved by the Board on June 25, 2026, is pending NCLT and regulatory approvals.
- ₹200 crore facility utilisation. Drawdowns under the shareholder-approved ₹200 crore loan and guarantee facility, approved via postal ballot on January 30, 2024, will be reported in subsequent filings.
Bottom line: This is a disclosed and audited record with clean revenue recognition and small contingent liabilities. The risk sits in two places: the Paints and Adhesives segment, where margins have halved but goodwill remains largely unimpaired, and the pattern of amalgamations and exceptional charges that reshape reported earnings. Watch the August 2026 AGM vote on MD remuneration and the next goodwill impairment test.